<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268706</url>
  </required_header>
  <id_info>
    <org_study_id>TESSCAR001</org_study_id>
    <nct_id>NCT04268706</nct_id>
  </id_info>
  <brief_title>Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)</brief_title>
  <official_title>A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory CD30 Positive Classical Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tessa Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tessa Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety&#xD;
      and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or&#xD;
      refractory CD30+ classical Hodgkin Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Pilot part of the study will evaluate the safety, tolerability, and preliminary antitumor&#xD;
      efficacy of CD30.CAR-T. The Pivotal part of the study will evaluate antitumor efficacy and&#xD;
      further evaluate safety and tolerability. All study eligibility requirements, assessments,&#xD;
      procedures, and follow-up are the same for patients in both Pilot and Pivotal parts of the&#xD;
      study.&#xD;
&#xD;
      Subjects who meet eligibility criteria will have their blood drawn by leukapheresis for&#xD;
      manufacture the CD30.CAR-T cells. Subjects are allowed bridging chemotherapy, as per&#xD;
      Investigator choice, while waiting for production of CD30.CAR-T. Lymphodepletion (LD) with&#xD;
      fludarabine and bendamustine will be administered for 3 consecutive days starting on Day -5&#xD;
      to Day -3, prior to CD30.CAR-T infusion, which will be administered on Day 0 as a single IV&#xD;
      infusion. Depending on disease status, eligible subjects may receive up to a total of two&#xD;
      CD30.CAR-T infusions at the same dose, each with preceding LD chemotherapy.&#xD;
&#xD;
      Subjects will be closely monitored for safety and efficacy throughout the Treatment Period&#xD;
      until the end of study (EOS) visit at Month 24. Subjects will be followed for survival,&#xD;
      withdrawal of consent or study closure, whichever occurs first. Health Related Quality of&#xD;
      Life assessments will also be collected throughout the study. After the EOS visit, subjects&#xD;
      will enter the long-term follow-up phase (LTFU) which will include survival follow-up,&#xD;
      additional safety, efficacy and biomarker assessments, as clinically indicated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 2036</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pilot: Safety of autologous CD30.CAR-T</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pivotal: Anti-tumor effect of autologous CD30.CAR-T using objective response rate (ORR) as assessed by an Independent Radiology Review Committee (IRRC) per the Revised Criteria for Response Assessment: The Lugano Classification (Cheson, 2014)</measure>
    <time_frame>As early as 6 weeks after CD30.CAR-T treatment</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pilot: Antitumor efficacy of autologous CD30.CAR-T using objective response rate (ORR) as assessed by an Independent Radiology Review Committee (IRRC) per the Revised Criteria for Response Assessment: The Lugano Classification (Cheson et al., 2014)</measure>
    <time_frame>As early as 6 weeks after CD30.CAR-T treatment</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot: Duration of Response</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot: Progression Free Survival</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot: Overall Survival</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot: Health Related quality of life (HRQoL) questionnaire</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pivotal: Number of patients with adverse events as a measure of safety and tolerability of CD30.CART cells</measure>
    <time_frame>As early as 6 weeks after CD30.CAR-T treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pivotal: Objective response rate (ORR as assessed by IRRC) per the Revised Criteria for Response Assessment: The Lugano Classification (Cheson, 2014)</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pivotal: Progression Free Survival (PFS)</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pivotal: Duration of Response (DOR)</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pivotal: Overall Survival</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pivotal: Health Related quality of life (HRQoL) questionnaire</measure>
    <time_frame>Minimum 24 months post-CD30.CAR-T infusion</time_frame>
    <description>HRQoL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Hodgkin Lymphoma, Adult</condition>
  <condition>Hodgkin Disease Recurrent</condition>
  <condition>Hodgkin Disease Refractory</condition>
  <condition>Hodgkin Disease, Pediatric</condition>
  <arm_group>
    <arm_group_label>CD30 positive r/r classical Hodgkin Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory classical Hodgkin Lymphoma who have failed 3 prior lines of treatment, which may include a prior autologous and/or allogeneic stem cell transplant.&#xD;
Patients will be treated with autologous CD30.CAR-T cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD30.CAR-T</intervention_name>
    <description>Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.</description>
    <arm_group_label>CD30 positive r/r classical Hodgkin Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days</description>
    <arm_group_label>CD30 positive r/r classical Hodgkin Lymphoma</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days</description>
    <arm_group_label>CD30 positive r/r classical Hodgkin Lymphoma</arm_group_label>
    <other_name>Bendeka</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligibility is determined prior to blood collection . Patients must satisfy the following&#xD;
        criteria to be enrolled in the study:&#xD;
&#xD;
          1. Signed Informed Consent Form&#xD;
&#xD;
          2. Male or female patients who are 12 - 75 years of age&#xD;
&#xD;
          3. Histologically confirmed classical Hodgkin Lymphoma&#xD;
&#xD;
          4. Relapsed or refractory cHL that has failed at least 3 prior lines of therapy,&#xD;
             including:&#xD;
&#xD;
               -  chemotherapy&#xD;
&#xD;
               -  BV and/or&#xD;
&#xD;
               -  PD-1 inhibitor Patients may have previously received an autologous and/or&#xD;
                  allogeneic stem cell transplant&#xD;
&#xD;
          5. CD30-positive tumor&#xD;
&#xD;
          6. At least 1 measurable lesion according to The Lugano Classification&#xD;
&#xD;
          7. Laboratory parameters: Hematological, renal and hepatic functions, and coagulation&#xD;
             parameters&#xD;
&#xD;
               -  Hgb ≥ 8.0 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × ULN&#xD;
&#xD;
               -  AST and ALT ≤ 5 × the ULN&#xD;
&#xD;
               -  CrCl &gt; 45 mL/min&#xD;
&#xD;
               -  ANC &gt;1,000/µL&#xD;
&#xD;
               -  Platelets &gt;75,000/µL&#xD;
&#xD;
               -  PT or INR ≤ 1.5 × ULN; PTT or aPTT ≤ 1.5 × ULN&#xD;
&#xD;
          8. ECOG PS of 0 to 1 or equivalent [either Karnofsky PS (for patients ≥ 16 year of age)&#xD;
             or Lansky PS (for patients &lt; 16 years of age)]&#xD;
&#xD;
          9. Anticipated life expectancy &gt; 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of lymphomatous involvement of central nervous system (CNS)&#xD;
&#xD;
          2. Presence of clinically relevant or active seizure disorder, stroke, cerebrovascular&#xD;
             ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with&#xD;
             central nervous system (CNS) involvement&#xD;
&#xD;
          3. Active uncontrolled bleeding or a known bleeding diathesis&#xD;
&#xD;
          4. Inadequate pulmonary function defined as pulse oximetry &lt; 90% on room air&#xD;
&#xD;
          5. ECHO or MUGA with LVEF &lt; 45%&#xD;
&#xD;
          6. On-going treatment with immunosuppressive drugs or chronic systemic corticosteroids&#xD;
&#xD;
          7. Having received:&#xD;
&#xD;
               -  Anti-CD30 antibody-based therapy within 4 weeks prior to CD30.CAR-T infusion&#xD;
&#xD;
               -  Prior investigational CD30.CAR-T&#xD;
&#xD;
               -  CD30 bispecific agent within 8 weeks prior to CD30.CAR-T infusion&#xD;
&#xD;
               -  Autologous HSCT within 90 days or allogeneic HSCT within 180 days prior to&#xD;
                  CD30.CAR-T infusion&#xD;
&#xD;
          8. Currently receiving any investigational agents within 4 weeks prior to study&#xD;
             enrollment; or received any tumor vaccines within 6 weeks prior to CD30.CAR-T infusion&#xD;
&#xD;
          9. Active acute or chronic graft versus host disease (GVHD) requiring immune suppression&#xD;
             regardless of grade&#xD;
&#xD;
         10. Evidence of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
         11. Seropositive for and with evidence of active viral infection with hepatitis B virus&#xD;
             (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
         12. Unresolved &gt; Grade 1 non-hematologic toxicity associated with any prior treatments&#xD;
&#xD;
         13. History of hypersensitivity reactions to murine protein-containing products or other&#xD;
             product excipients&#xD;
&#xD;
         14. Symptomatic cardiovascular disease: Class III or IV according to the New York Heart&#xD;
             Association (NYHA) Functional Classification&#xD;
&#xD;
         15. Active second malignancy or history of another malignancy within the last 3 years&#xD;
&#xD;
         16. Women who are pregnant or intending to become pregnant; women who are breastfeeding;&#xD;
             persons with procreative potential not using and not willing to use 2 highly effective&#xD;
             methods of contraception&#xD;
&#xD;
         17. Any other serious, life-threatening, or unstable preexisting medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Heslop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>65 63840755</phone>
    <email>clinicaltrials@tessacell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Mei, MD</last_name>
      <phone>833-310-2278</phone>
      <email>mamei@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Riedell, MD</last_name>
      <phone>773-702-8412</phone>
      <email>Priedell@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Eckert, MD</last_name>
      <phone>773-702-2023</phone>
      <email>keckert@medicine.bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sue Rheingold, MD</last_name>
      <phone>215-590-5476</phone>
      <email>rheingold@chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Shinehouse, MD</last_name>
      <phone>267-425-7196</phone>
      <email>shinehousl@chop.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Flinn, MD</last_name>
      <phone>615-329-7274</phone>
      <email>iflinn@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sairah Ahmed, MD</last_name>
      <phone>713-794-4374</phone>
      <email>SAhmed3@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>r/r Hodgkin Lymphoma, CD30, adult, pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

